Press release

Siemens Healthineers Now Launching Sysmex CN-3000 and CN-6000 Hemostasis Systems

Published on August 12, 2021
<ul><li><b>The fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.</b></li><li><b>A broad menu of both routine and specialty coagulation assays from Siemens Healthineers can be performed on the Sysmex CN-3000 and CN-6000 Systems.</b></li><li><b>New and now available on the Sysmex CN Systems is the INNOVANCE Anti-Xa assay for automated heparin and direct oral anticoagulant testing.</b></li></ul><p>TARRYTOWN, N.Y., Aug 12, 2021 - Siemens Healthineers announced it is now launching to laboratories Sysmex's CN-3000 and CN-6000 Hemostasis Systems for mid- and high-volume coagulation testing.<sup>1,2</sup> A broad menu of both routine and specialty coagulation assays from Siemens Healthineers that help identify blood coagulation disorders such as abnormal blood clotting or bleeding can be performed on the Sysmex CN-3000 and CN-6000 Systems, offering laboratories a compact and comprehensive hemostasis testing solution. This includes the new Siemens Healthineers' INNOVANCE Anti-Xa assay<sup>1,2</sup> for heparin and direct oral anticoagulant testing (DOAC).</p><p>"Siemens Healthineers and Sysmex's 25-year partnership in hemostasis enables us to deliver both quality and comprehensive hemostasis testing solutions to laboratories of all sizes across the world," said Deepak Nath, PhD, President of Laboratory Diagnostics for Siemens Healthineers.</p><p>Siemens Healthineers and Sysmex provide hemostasis offerings to laboratories that are used to test for blood clotting disorders and preoperative bleeding risk management, and to monitor patients on anticoagulant therapy medications. New to the Siemens Healthineers' test menu, and now available on the Sysmex CN-3000 and CN-6000 Systems and other fully automated Sysmex and Siemens Healthineers platforms, is the INNOVANCE Anti-Xa assay. The ready-to-use, liquid-reagent heparin and DOAC assay delivers precise results without reagent reconstitution or waiting before use. The assay streamlines handling, reduces ordering complexity by enabling labs to test for heparin, as well as direct oral anticoagulants rivaroxaban and apixaban with one combined assay, and offers labs an economical testing solution for heparin and DOAC testing.</p><p>The Sysmex CN-3000 and CN-6000 Systems are designed to integrate with the Siemens Healthineers Atellica Data Manager and Aptio Automation to further streamline a hands-free workflow in the laboratory and to automate sample processing—including sample preparation as well as storage, refrigeration, and retrieval. With the ability to connect to Atellica Process Manager, labs can manage testing processes from a centralized location, while also gaining access to analytics to baseline and track key performance indicators such as turnaround time or problem samples. When connected to Atellica Data Manager, advanced algorithms can automatically determine next steps in sample processing and routing helping labs to standardize testing protocols across multiple systems and locations. </p><p> For more information, visit <a href="" target="_blank" data-ste-link-id="3337100395.application/07000467:3386191886.smex-cn-3000-6000-systems:0517526322"></a>&nbsp;<br></p>

Download image


Siemens Healthineers 2021

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at